AXA Framlington Biotech R Class Acc

Performance History30/09/2018
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc
Fund45.311.2-5.98.518.4
+/-Cat6.7-2.3-1.9-1.74.5
+/-B’mrk6.3-2.7-10.70.66.5
 
Key Stats
NAV
16/10/2018
 GBX 180.00
Day Change -1.04%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
30/09/2018
 GBP 544.71
Share Class Size (Mil)
16/10/2018
 GBP 122.45
Max Initial Charge 5.50%
Ongoing Charge
19/02/2018
  1.82%
Investment Objective: AXA Framlington Biotech R Class Acc
The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.
Returns
Trailing Returns (GBP)16/10/2018
YTD6.57
3 Years Annualised6.01
5 Years Annualised14.25
10 Years Annualised18.67
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMSCI World/Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech R Class Acc31/08/2018
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.580.0095.58
Bond0.000.000.00
Property0.000.000.00
Cash5.070.644.42
Other0.000.000.00
Top 5 Regions%
United States88.80
Eurozone6.72
United Kingdom2.55
Europe - ex Euro1.93
Canada0.00
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Biogen IncHealthcareHealthcare9.78
Celgene CorpHealthcareHealthcare7.73
Alexion Pharmaceuticals IncHealthcareHealthcare6.28
Gilead Sciences IncHealthcareHealthcare6.27
Regeneron Pharmaceuticals IncHealthcareHealthcare5.27
AXA Framlington Biotech R Class Acc